Podcasts about myeloproliferative neoplasms

This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

- Overview of Myeloproliferative Neoplasm-Related Weight Changes - Causes of Your Weight Loss or Weight Gain - Strategies for Managing Your Weight - Common Weight-Related, Eating, & Hydration Questions to Ask Your Doctor & Health Care Team - Nutrition & Hydration Concerns & Tips - Benefits of Physical Activity - How Meditation & Integrative Medicine May Help You Cope - Guidelines to Prepare for Telehealth/Telemedicine Appointments Including: Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts

- Review of the Treatments for Polycythemia Vera (PV), Essential Thrombocythemia (ET), & Myelofibrosis (MF) & Common Treatment Side Effects - Reducing Complications of Myeloproliferative Neoplasms (MPNs): What You Need to Know & Do - Key Concerns to Discuss with Your Doctor & Health Care Team, Including Treatment Side Effects & Symptoms Requiring Immediate Attention Between Appointments - Keeping a Journal of Specific Side Effects, Symptoms, Discomfort & Pain to Report to Your Doctor - Know the Warning Signs of a Potential Medical Emergency & What to Do - How Being More Assertive May Improve Your Care & Quality of Life - Questions for Our Panel of Experts

- Overview of Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) - Staging & Diagnosing - Current Standard of Care & New Treatment Approaches - Understanding Common Symptoms - Working with Your Health Care Team to Manage Your Symptoms - Strategies to Reduce Potential Complications of MPNs - The Important Role of Clinical Trials - How Research Increases Your Treatment Options - Communicating with Your Health Care Team about Staging & Progression - Talking with Your Doctor about What Symptoms Should Prompt You or Your Caregiver to Call the Office - Integrative Medicine, Quality of Life & Concerns About Life Expectancy - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence & Discussion of OpenNotes - Questions for Our Panel of Experts

Send us a textLet's talk about the BCR:ABL negative MPNs! Written by Dr. Sarah Ge (Internal Medicine Resident), reviewed by Dr. Christopher Hillis @HemeHillis (Hematology) and Dr. John Neary @jddneary (General Internal Medicine). Infographic by Dr. Caitlyn Vlasschaert @DrFlashHeart (Internal Medicine Resident).Support the show

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics: Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35) Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21) Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10) Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33) Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38) Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08) Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56) Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48) Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18) Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56) CME information and select publications

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASH24/MPN).

- Overview of MPN-Related Weight Changes - Causes of Your Weight Loss or Weight Gain - Strategies for Managing Your Weight - Common Weight-Related, Eating, & Hydration Questions to Ask Your Doctor & Health Care Team - Nutrition & Hydration Concerns & Tips - Benefits of Physical Activity - How Meditation & Integrative Medicine May Help You Cope - Guidelines to Prepare for Telehealth/Telemedicine Appointments including: Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

In the episode, we explore the family of diseases called myeloproliferative neoplasms (MPNs). Dr. Anand Patel and Dr. Olatoyosi Odenike… The post Living with Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS.

In the episode, we explore the family of diseases called myeloproliferative neoplasms (MPNs). Dr. Anand Patel and Dr. Olatoyosi Odenike… The post Living with Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS. The post Living with Myeloproliferative Neoplasms (MPNs) appeared first on The Bloodline with LLS.

- Review of the Treatments of Polycythemia Vera (PV), Essential Thrombocythemia (ET) & Myelofibrosis (MF) & Common Treatment Side Effects - Reducing Complications of Myeloproliferative Neoplasms (MPNs): What You Need to Know & Do - Key Concerns to Discuss with Your Doctor & Health Care Team, Including Treatment Side Effects & Symptoms Requiring Immediate Attention Between Appointments - Keeping a Journal of Specific Side Effects, Symptoms, Discomfort & Pain to Report to Your Doctor - Know the Warning Signs of a Potential Medical Emergency & What to Do - How Being More Assertive May Improve Your Care & Quality of Life - Questions to Ask Our Panel of Experts

- Overview of Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) - Staging & Diagnosing - Current Standard of Care & New Treatment Approaches - Understanding Common Symptoms - Working with Your Health Care Team to Manage Your Symptoms - Strategies to Reduce Potential Complications of MPN - The Important Role of Clinical Trials - How Research Increases Your Treatment Options - Communicating with Your Health Care Team About Staging & Progression - Talking with Your Doctor About What Symptoms Should Prompt You or Your Caregiver to Call the Office - Integrative Medicine, Quality of Life & Concerns About Life Expectancy - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:Navitoclax (BCL-XL/BCL-2 inhibitor)Pelabresib (BET inhibitor)Imetelstat (telomerase inhibitor)Luspatercept (erythroid maturation agent)Additional strategiesPresenter:  Jacqueline S. Garcia, MDAssistant Professor of MedicineHarvard Medical SchoolDana-Farber Cancer InstituteBoston, MassachusettsLink to the full program here. https://bit.ly/47z8WCV  

Commentary by Dr. Paola Guglielmelli

Myeloproliferative Neoplasms (MPNS) is an umbrella term that includes myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV). In this… The post Living A Full Life: Exploring Myeloproliferative Neoplasms (MPNs) first appeared on The Bloodline with LLS.

Myeloproliferative Neoplasms (MPNS) is an umbrella term that includes myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV). In this… The post Living A Full Life: Exploring Myeloproliferative Neoplasms (MPNs) appeared first on The Bloodline with LLS.

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics: Introduction (0:00) Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28) New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13) Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59) Overview of Acute Myeloid Leukemia (AML) (1:15:18) Targeted Therapy for AML (1:26:02) NCPD information and select publications

In this episode Associate Editor, Dr. Mario Cazzola discusses the review series on Classical Myeloproliferative Neoplasms, with authors, Dr. Ann Mullaly and Dr. Alison Moliterno.  

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:Overall approach to treatmentUse of JAK inhibitors for treating myelofibrosisTreating patients with low plateletsDefining JAK inhibitor failureUnmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approachesPresenters: John Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Adult Leukemia ProgramLeader, Myeloproliferative Disorders Clinical Research ProgramDivision of Hematology/OncologyTisch Cancer InstituteNew York, New York Ruben A. Mesa, MD, FACPExecutive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer CenterEnterprise Senior Vice President, Atrium HealthPresident, Enterprise Cancer Service LineVice Dean for Cancer Programs, Wake Forest University School of MedicineProfessor of Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina

As clinicians continue to seek new ways to provide the best patient care for patients with myeloproliferative neoplasms, a group of rare hematological cancers which can be challenging to treat, hear how recent guideline and treatment updates by the National Comprehensive Cancer Network (NCCN) can optimize care for patients with myeloproliferative neoplasms. In this episode, CANCER BUZZ speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. about the impact of these new guidelines. “Every single patient is very different in the symptoms they present with, the duration of the disease, and what their goals are in receiving therapy. Ultimately, that often means that we don't have a one-size-fits-all treatment strategy…Instead, we have a variety of treatment options that can provide different benefits for patients and when you have that, it merely comes down to what makes sense for the patient, what makes sense for the disease, what makes sense for the patient's family, and what you feel as a physician is the most appropriate for the patient.” – Andrew Kuykendall, MD This is the fourth video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs). This episode is supported by Incyte. Guests: Andrew Kuykendall, MD,  Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms  

As myeloproliferative neoplasms carry a significant symptom burden and oftentimes can require lifelong care coordination and close monitoring, hear how a strong multidisciplinary approach can impact shared decision-making and patient engagement. In this episode, CANCER BUZZ speaks with speaks with Andrew Kuykendall, MD, assistant member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla. and Katherine Mast, BSN, RN at Moffit Cancer Center about the impact of multidisciplinary coordination on patient care and outcomes for patients with myeloproliferative neoplasms. “When we talk about shared-decision making, I think we can talk about it in the sense of sharing that decision-making with the patient, and also sharing it with the entire [multidisciplinary] team. We like to create that engagement where we [the multidisciplinary team] are all there together—to recount what is going on, refocus what our goals of therapy are, discuss what the different options are, and then put it in the patient's hands to say ‘of these options, what do you think makes the most sense for what your goals are?'” – Andrew Kuykendall, MD “Where we can make some of the biggest impact is having people on our team who really understand what it's like to have an MPN because we see this group of patients constantly. Having one person that they can come to is wonderful, but having multiple people that are on their team that they know are there to help and answer questions can be really profoundly impactful, especially if they have a rare disease and their local hematologist/oncologist may not know as much about it.” – Katherine Mast, BSN, RN This is the third video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).” This episode is supported by Incyte. Guests: Andrew Kuykendall, MD,  Assistant Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL  Katherine Mast, BSN, RN  Registered Nurse Moffitt Cancer Center Tampa, FL Resources: Myeloproliferative Neoplasms (cancersupportcommunity.org) National Comprehensive Cancer Network (NCCN) Guidelines: Myeloproliferative Neoplasms  

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts' thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

Featuring perspectives from Dr Srdan Verstovsek, including the following topics: Overview of current issues in the management of myeloproliferative neoplasms (MPN) (0:00) Treatment strategies for patients with myelofibrosis (MF) progressing after ruxolitinib (14:46) Correlation of molecular characterization and response to ruxolitinib in patients with MF (23:57) Rationale for and efficacy with combined inhibition of Bcl-2 and Bcl-xL for MPN (44:38)   Targeting calreticulin mutations for MPN (52:02) Advances in the management of polycythemia vera (57:54)  Developments in the care of patients with essential thrombocythemia (1:04:43)  Future directions in the clinical care of patients with MPN (1:12:46) CME information and select publications

Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/MPN).

Featuring a discussion on newly presented data with myelofibrosis, polycythemia vera and essential thrombocythemia with Dr Srdan Verstovsek, moderated by Dr Neil Love.

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts' thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisContent for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3X3x6jX

Season 3 Episode 15- Myeloproliferative Neoplasms, Pankit Vachhani, MDOn the Season 3 finale we sit down with Dr. Pankit Vachhani to discuss myeloproliferative neoplasms and specifically myelofibrosis. Dr. Vachhani is an Assistant Professor of Medicine at the University of Alabama at Birmingham (UAB) and Associate Scientist of Experimental Therapeutics. A graduate of Weill Cornell Medical College in Qatar in 2012, Dr. Vachhani went on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY.                                             At UAB, he is involved in various clinical trials as a principal investigator.  He leads the Leukemia/BMT working group and serves as the Medical Director of the Clinical Research Unit (CRU). His primary research interest is in hematological malignancies, particularly myeloproliferative neoplasms and AML, where he focuses on experimental therapeutics. He also serves as a panelist helping create the AML and MPN Treatment Guidelines for the National Comprehensive Cancer Network.

In the last 10 years, there have been many advancements in the treatment of MPNs. In combination with a better overall understanding of its causes and what contributes to its progression, Dr. Dawn Maze says it is a very "exciting" time in the treatment of MPNs. In this episode, Dr. Maze, a hematologist at Toronto's Princess Margaret Cancer Centre, explains what MPNs are, how they are treated and the challenges those diagnosed with an MPN might face.

Featuring perspectives from Dr Prithviraj Bose, including the following topics: Key myeloproliferative neoplasms (MPN) presentations from ASH 2021  (18:41) MPN trials in progress (11:38) Predictors of adverse events and prognosis from MPN therapy; novel drugs in MPN treatment (18:41) CME information and select publications

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMPN22).

Featuring a discussion on recent advances in the treatment of myeloproliferative neoplasms from the 2021 ASH annual meeting with Dr Prithviraj Bose, moderated by Dr Neil Love.

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of Wisconsin, Milwaukee, US) and Claire Harrison (Guy's and St Thomas' NHS Foundation Trust, London, UK). We asked, Patient follow-up in myeloproliferative neoplasms: Best practices and myths. In this podcast, Michaelis and Harrison discuss the best practices in MPN, in particular in regards to diagnosis. They also discuss the new data that was presented at ASH 2021, such as the MOMENTUM (NCT04173494) study and momelotinib. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient's—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the UK, using the refined genetic sequencing tool: single cell multi omics (Abstract 3). The ASH Plenary Session heard an inspiring talk on this from Oxford scientist Alba Rodriguez-Meira—winner of an ASH Abstract Achievement Award. And after the session, OT reporter Peter Goodwin tracked down her colleague, senior author Adam J. Meade, at the Weatherall Institute of Molecular Medicine in Oxford University.

This week, we'll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

This year, only about 14,500 people in the U.S. will be diagnosed with a myeloproliferative neoplasm, MPN, a rare group of blood cancers. Living with a rare cancer, like an MPN, comes with a unique set of challenges. The diagnosis can be hard to understand, and treatment is often “watch-and-wait” or symptom management only. In honor of Blood Cancer Awareness Month in September and MPN Awareness Day on September 11, join us to shine a light on these rare cancers. Guest host Linda House welcomes back to the show Melissa Wright, LMSW, OSW-C, Program Director at Gilda's Club Quad Cities to talk more about how to live well with a rare cancer.

Myeloproliferative neoplasms, -MPNs- are a group of blood cancers that cause the body to overproduce blood cells in the bone marrow due to genetic mutations originating in stem cells. Last year, only about 14,500 people in the United States were diagnosed with an MPN. Many people are often unaware that this group of cancers exist. Each year the Cancer Support Community strives to “shine the light on MPNs” and raise awareness of MPNs and the impact of living with a rare type of cancer. This year is no different. This Thursday, September 8, is MPN Awareness Day, and to commemorate the day, guest host Linda House offers tips for living well with an MPN.

Only about 14,500 people in the U.S. will be diagnosed with an MPN this year, and the number for polycythemia vera, a type of MPN, is even less—about 22 cases per 100,000 people. On this episode of Frankly Speaking About Cancer, we'll learn more about polycythemia vera, as well as tips for managing a rare cancer.